PMV Pharmaceuticals Inc expected to post a loss of 37 cents a share - Earnings Preview

Pmv Pharmaceuticals

05/05/2025 14:44

PMV Pharmaceuticals Inc PMVP.OQ PMVP.O is expected to show no change in quarterly revenue when it reports  results on May 7 (estimated) for the period ending March 31 2025

​LSEG's mean analyst estimate for PMV Pharmaceuticals Inc is for a loss of 37 cents per share.

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts had fallen by about 1.1% in the last three months. ​

Wall Street's median 12-month price target for PMV Pharmaceuticals Inc is $6.00​, above​ its last closing price of $1.00. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATEÂŪ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.39
-0.38
-0.45
Missed
-18.2
Sep. 30 2024
-0.36
-0.35
-0.37
Missed
-5.4
Jun. 30 2024
-0.35
-0.35
-0.02
Beat
94.3​
Mar. 31 2024
-0.35
-0.36
-0.30
Beat
16.8
​​Dec. 31 2023
-0.38
-0.39
-0.31
Beat
19.7
Sep. 30 2023
-0.45
-0.45
-0.34
Beat
23.8​
Jun. 30 2023
-0.46
-0.47
-0.38
Beat
20
Mar. 31 2023
-0.44
-0.46
-0.42
Beat
8.4

This summary was machine generated May 5 at 13:44 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)